McGill University-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8014130)
◆英語タイトル:McGill University - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014130
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:59
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
McGill University (McGill) is a research based educational institute. The university offers undergraduate, graduate and post-graduate courses. It provides academic courses across various disciplines including agricultural and environmental sciences, arts, dentistry, education, engineering, law, management, medicine, music and science among others. The university carries research and licensing technologies in several domains which include agriculture, mechanical and materials, genomics and proteomics, nanotechnologies, climate research, biomedical, network communications, food technology, clean technology, therapeutic agents. McGill works in collaboration with hospitals, research institutions and health centers such as Jewish General Hospital, The Shriners Hospital, St. Mary’s Hospital Center and Douglas Mental Health University Institute. McGill is headquartered in Montreal, Quebec, Canada.

McGill University – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
McGill University, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
McGill University, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
McGill University, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
McGill University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
McGill University, Medical Devices Deals, 2011 to YTD 2017 10
McGill University, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
McGill University, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Lead Discovery Center Enters into Research Agreement with McGill University 13
Proove Biosciences Enters into Partnership with McGill University 14
B Cell Design Enters into R&D Agreement with McGill University 15
IASO BioMed Enters into Research Agreement with Research Institute of the McGill University 16
Cyclenium Pharma Enters into Research Agreement with McGill University 17
Neomed Institute Partners with McGill University 18
MSBi Valorisation, McGill University and Research Institute of the McGill University Health Centre Form Partnership 19
Viteava Pharma Enters Into Research Agreement With Mcgill University 20
PharmaNet Canada Forms Joint Venture With The Research Institute Of McGill University Health Centre 21
GlaxoSmithKline Enters Into Co-Development Agreement With McGill University 22
Licensing Agreements 23
Corbin Therapeutics Enters into License Agreement with McGill University 23
IASO BioMed Enters into Licensing Agreement with McGill University 24
AUM LifeTech Enters into Licensing Agreement with McGill University 25
Kinex Pharma Enters into Licensing Agreement with Hong Kong Polytechnic University and McGill University 26
PsychoGenics Enters into Licensing Agreement with McGill University for McGill-R-Thy I-APP 27
Domain Therapeutics Extends its Licensing Agreement with Universite de Montreal and McGill University 28
Viteava Pharma Enters Into Licensing Agreement For Intellectual Property Portfolio Of Analogs And Derivatives 30
Raptor Pharma Enters Into Licensing Agreement With McGill University For IP Rights Related To Malaria 32
Asset Transactions 33
Kanyr Pharma Acquires Rights for Two Cancer Programs from McGill University 33
McGill University – Key Competitors 34
McGill University – Key Employees 35
McGill University – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Joint Venture 36
Recent Developments 37
Strategy And Business Planning 37
Jan 09, 2017: Amorchem Spins Out Its USP15-deubiquitinylation (DUB) Drug Discovery Platform Into Corbin Therapeutics, With A First 1M $ Seed Investment 37
Government and Public Interest 38
Oct 23, 2017: Transformative donation of $16 million establishes new autism research centre at the Montreal Neurological Institute 38
Oct 13, 2017: New mechanism detected in Alzheimer’s disease 39
Oct 13, 2017: Neurotechnological innovation and organ-on-a-chip engineering centres receive more than $10 million in new funding 40
Sep 06, 2017: Scientists link 153 new genetic variants to osteoporosis in largest ever study 41
May 15, 2017: Diabetes drug may help symptoms of autism associated condition 42
Jan 09, 2017: Breakthrough in MS treatment 43
Oct 18, 2016: RI-MUHC researchers discover new path to stop the spread of cancer 44
Oct 03, 2016: KalGene gears up to manufacture and test promising Alzheimer’s treatment with NRC, McGill and CIMTEC 45
Sep 22, 2016: Kenneth Rainin Foundation Awards Over $3 Million to High-Risk, High Reward Inflammatory Bowel Disease Research Projects 46
Sep 15, 2016: €12.6 Million Awarded to 3 Projects in Global Effort to End Progressive Multiple Sclerosis 48
Sep 07, 2016: Medication against schizophrenia inhibits pancreatic cancer 50
Sep 06, 2016: McGill wins $84 million grant for neuroscience 51
Sep 01, 2016: Ferring Canada Donates $2 Million to McGill University 52
Aug 15, 2016: Legions of nanorobots target cancerous tumours with precision – Administering anti-cancer drugs redefined 53
Aug 01, 2016: Adverse Effects and Incretin-based Drugs for Diabetes 54
Apr 20, 2016: Brighter prospects for chronic pain 55
Feb 15, 2016: Vulnerability to depression linked to noradrenaline 56
Jan 20, 2016: Using light for targeted drug delivery could help fight tumors, local infections 57
Other Significant Developments 58
Oct 20, 2016: Easing the burden of terminal illness 58
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59

List of Tables
McGill University, Pharmaceuticals & Healthcare, Key Facts 2
McGill University, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
McGill University, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
McGill University, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
McGill University, Deals By Therapy Area, 2011 to YTD 2017 9
McGill University, Medical Devices Deals, 2011 to YTD 2017 10
McGill University, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Lead Discovery Center Enters into Research Agreement with McGill University 13
Proove Biosciences Enters into Partnership with McGill University 14
B Cell Design Enters into R&D Agreement with McGill University 15
IASO BioMed Enters into Research Agreement with Research Institute of the McGill University 16
Cyclenium Pharma Enters into Research Agreement with McGill University 17
Neomed Institute Partners with McGill University 18
MSBi Valorisation, McGill University and Research Institute of the McGill University Health Centre Form Partnership 19
Viteava Pharma Enters Into Research Agreement With Mcgill University 20
PharmaNet Canada Forms Joint Venture With The Research Institute Of McGill University Health Centre 21
GlaxoSmithKline Enters Into Co-Development Agreement With McGill University 22
Corbin Therapeutics Enters into License Agreement with McGill University 23
IASO BioMed Enters into Licensing Agreement with McGill University 24
AUM LifeTech Enters into Licensing Agreement with McGill University 25
Kinex Pharma Enters into Licensing Agreement with Hong Kong Polytechnic University and McGill University 26
PsychoGenics Enters into Licensing Agreement with McGill University for McGill-R-Thy I-APP 27
Domain Therapeutics Extends its Licensing Agreement with Universite de Montreal and McGill University 28
Viteava Pharma Enters Into Licensing Agreement For Intellectual Property Portfolio Of Analogs And Derivatives 30
Raptor Pharma Enters Into Licensing Agreement With McGill University For IP Rights Related To Malaria 32
Kanyr Pharma Acquires Rights for Two Cancer Programs from McGill University 33
McGill University, Key Competitors 34
McGill University, Key Employees 35
McGill University, Subsidiaries 36
McGill University, Joint Venture 36

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ McGill University-製薬・医療分野:企業M&A・提携分析(McGill University - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆